title: Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations.
abstract: Coenzyme Q(10) (CoQ(10)) has been used as a drug for chronic heart failure. Furthermore, various biological effects of CoQ(10) have also been applied for food supplements and cosmetics. However, CoQ(10) was found to be poorly soluble in water, so that its bioavailability was low and variable depending on food intake. In the present investigation, a novel liquid (nano-emulsion, NE) and water-soluble powder formulations, including cyclodextrin-Q10 complex (CoQ(10)-CD) and dry-emulsion (DE), were prepared. The physicochemical properties of each formulation were characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), powder X-ray diffractometry (PXRD), and differential scanning calorimetry (DSC). In all powder formulations prepared, CoQ(10) existed mainly as an amorphous form as determined by PXRD and DSC, and each powder formulation exhibited high solubility and dispersibility in water resulting in the formation of a nano-sized emulsion (NE; 60nm) and micron sized particles (DEs and CoQ(10)-CD; 0.77-2.4microm). The pharmacokinetic study of each dosage form, in comparison to a CoQ(10) crystal suspension, was also carried out in rats after a single oral dose. Although similar kinetic values were seen with T(max) of 1.5 and 1.7h, respectively, for NE and crystalline CoQ(10), NE exhibited ca 1.7-fold higher AUC and C(max) than the crystalline CoQ(10).
authors.affiliation: Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka, Japan.
authors.forename: Junya
authors.initials: J
authors.lastname: Hatanaka
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kimura
authors.forename: Zhogn
authors.initials: Z
authors.lastname: Lai-Fu
authors.forename: Satomi
authors.initials: S
authors.lastname: Onoue
authors.forename: Shizuo
authors.initials: S
authors.lastname: Yamada
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D018360:Crystallography, X-Ray; D003505:Cyclodextrins / Q000737:chemistry; D004655:Emulsions; D008027:Light; D008297:Male; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D033362:Powder Diffraction; D011208:Powders; D051381:Rats; D017207:Rats, Sprague-Dawley; D012542:Scattering, Radiation; D012995:Solubility; D013499:Surface Properties; D013678:Technology, Pharmaceutical / Q000379:methods; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D014867:Water / Q000737:chemistry*
chemical_list: D003505:Cyclodextrins; D004655:Emulsions; D011208:Powders; D014867:Water; D014451:Ubiquinone; C024989:coenzyme Q10